Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts
المؤلفون المشاركون
Liao, Ming-juan
Ye, Mei-na
Zhou, Rui-juan
Sheng, Jia-yu
Chen, Hong-feng
المصدر
Evidence-Based Complementary and Alternative Medicine
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-10-19
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Yiqi formula (YF), a traditional herbal prescription, has long been used to treat triple-negative breast cancer (TNBC) patients.
The present study aims to investigate the effects and the related mechanism of YF for treatment of TNBC xenografts.
MDA-MB-231 (human TNBC) cells were subcutaneously injected into the second mammary fat pad of 40 female nude mice, which were divided into four groups: control, erlotinib (an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor), YF, and combination (YF plus erlotinib).
All treatments were administered orally for 30 days.
Inhibition rate of tumor weight by erlotinib, YF, and the combination was 26.47%, 17.24%, and 39.15%, respectively.
Western blotting showed that YF, erlotinib, and the combination downregulated p-EGFR ( P < 0.01 ) and p-Akt1 (pT308) ( P < 0.05 ) and upregulated PTEN compared with control, and the combination was more efficacious than erlotinib alone ( P < 0.05 ).
Similar results were detected by immunohistochemistry.
Real-time quantitative PCR showed that YF, erlotinib, and the combination increased PTEN mRNA ( P < 0.05 , P < 0.01 ) compared with control, and the combination was more efficacious than erlotinib alone ( P < 0.05 ).
In conclusion, YF can regulate the main components of the PI3K/Akt pathway in TNBC xenografts.
When YF was used in combination with erlotinib, it enhanced the antitumor effects of erlotinib on TNBC xenografts.
These findings suggest that YF is suitable to use for the treatment of TNBC patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Liao, Ming-juan& Ye, Mei-na& Zhou, Rui-juan& Sheng, Jia-yu& Chen, Hong-feng. 2014. Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts. Evidence-Based Complementary and Alternative Medicine،Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-1018766
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Liao, Ming-juan…[et al.]. Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts. Evidence-Based Complementary and Alternative Medicine No. 2014 (2014), pp.1-8.
https://search.emarefa.net/detail/BIM-1018766
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Liao, Ming-juan& Ye, Mei-na& Zhou, Rui-juan& Sheng, Jia-yu& Chen, Hong-feng. Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts. Evidence-Based Complementary and Alternative Medicine. 2014. Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-1018766
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1018766
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر